DCTH Delcath Systems, Inc. Stock Quote

DCTH [NASD]

Index	-	P/E	-	EPS (ttm)	-112.56	Insider Own	0.60%	Shs Outstand	6.59M	Perf Week	-11.70%
Market Cap	67.61M	Forward P/E	-	EPS next Y	-3.46	Insider Trans	-	Shs Float	5.02M	Perf Month	-25.60%
Income	-24.20M	PEG	-	EPS next Q	-0.98	Inst Own	42.30%	Short Float	7.19%	Perf Quarter	-51.92%
Sales	1.60M	P/S	42.26	EPS this Y	97.60%	Inst Trans	8.74%	Short Ratio	1.28	Perf Half Y	-10.39%
Book/sh	4.47	P/B	2.30	EPS next Y	13.70%	ROA	-118.90%	Target Price	-	Perf Year	28.25%
Cash/sh	4.34	P/C	2.36	EPS next 5Y	15.00%	ROE	-386.60%	52W Range	7.15 - 25.18	Perf YTD	-42.75%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-61.28%	Beta	0.57
Dividend %	-	Quick Ratio	3.10	Sales past 5Y	-1.20%	Gross Margin	61.10%	52W Low	36.36%	ATR	0.91
Employees	43	Current Ratio	3.20	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	30.19	Volatility	7.03% 6.35%
Optionable	No	Debt/Eq	0.09	EPS Q/Q	-100.40%	Profit Margin	-	Rel Volume	0.73	Prev Close	10.26
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 BMO	Payout	-	Avg Volume	282.16K	Price	9.75
Recom	1.50	SMA20	-17.27%	SMA50	-34.64%	SMA200	-32.46%	Volume	22,995	Change	-4.97%

Mar-09-21

Initiated

Canaccord Genuity

Buy

$24

Jan-05-21

Initiated

BTIG Research

Buy

$23

Jun-01-20

Initiated

Laidlaw

Buy

$19

May-11-21 08:00AM	Delcath Systems, Inc. Announces First Quarter 2021 Results GlobeNewswire
05:45AM	Delcath Systems, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 02:33AM	Who Has Been Buying Delcath Systems, Inc. (NASDAQ:DCTH) Shares? Simply Wall St.
Apr-30-21 04:01PM	Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results GlobeNewswire -5.85%
09:00AM	Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-21-21 08:38AM	Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom GlobeNewswire
Mar-31-21 02:55PM	Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation GlobeNewswire -23.71%
08:06AM	Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study Benzinga
07:45AM	Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time GlobeNewswire
07:30AM	Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma GlobeNewswire
05:45AM	Delcath Systems, Inc. to Host Earnings Call ACCESSWIRE
Mar-24-21 04:01PM	Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results GlobeNewswire
Mar-08-21 09:00AM	Delcath Systems to Participate at Upcoming Virtual Investor Conferences GlobeNewswire
Feb-11-21 09:00AM	Delcath Systems to Participate at Upcoming Virtual Investor Conferences GlobeNewswire
Jan-11-21 10:56AM	Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire
Dec-11-20 10:31AM	Delcath Systems Announces Completion of Underwritten Public Offering GlobeNewswire
Dec-09-20 08:00AM	Delcath Systems Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-08-20 04:01PM	Delcath Systems Announces Proposed Public Offering of Common Stock GlobeNewswire +6.98%
Dec-07-20 07:30AM	Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations GlobeNewswire
Nov-11-20 08:00AM	Delcath Systems, Inc. Announces Third Quarter 2020 Results GlobeNewswire
Nov-02-20 04:01PM	Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020 GlobeNewswire
09:00AM	Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results GlobeNewswire
Oct-29-20 07:30AM	Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma GlobeNewswire
Oct-01-20 04:07PM	Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer GlobeNewswire
Sep-28-20 10:50AM	Encode Ideas, L.P. to Host Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System's Phase 3 FOCUS Study Newsfile +9.34%
Sep-10-20 09:00AM	Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Sep-02-20 05:36PM	LD Micro 360 Companies Set to Present this Week. ACCESSWIRE
Aug-25-20 04:01PM	Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET GlobeNewswire
Aug-13-20 04:01PM	Delcath Systems, Inc. Announces Second Quarter 2020 Results GlobeNewswire
Aug-06-20 04:01PM	Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results GlobeNewswire
Aug-05-20 09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Aug-03-20 01:48PM	Delcath to Present at Canaccord Genuity 40th Annual Growth Conference GlobeNewswire
May-26-20 08:30AM	Delcath Announces Leadership Transition GlobeNewswire +5.64%
May-19-20 08:30AM	Encode Ideas, L.P. Announces the Initiation of Research Coverage on Delcath Systems, Inc. Newsfile
May-15-20 06:30AM	Delcath Announces First Quarter 2020 Results GlobeNewswire -5.16%
May-05-20 04:05PM	Delcath Systems Closes $22.0 Million Public Offering of Common Stock GlobeNewswire +6.00%
May-01-20 10:17AM	Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market GlobeNewswire -39.92%
Feb-19-20 08:30AM	Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors GlobeNewswire
Jan-13-20 08:30AM	Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma GlobeNewswire
Dec-19-19 08:30AM	Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019 GlobeNewswire -7.13%
Dec-03-19 08:30AM	Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019 GlobeNewswire
Oct-22-19 07:27AM	Delcath Systems Announces Postponement of Reverse Stock Split GlobeNewswire
Oct-18-19 08:00AM	Delcath Systems Announces Ratio for Reverse Stock Split GlobeNewswire -5.00%
Oct-15-19 08:00AM	MicroCap Rodeo - Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE +5.00%
Oct-08-19 08:00AM	Delcath Systems to Present at the MicroCap Rodeo Investor Conference GlobeNewswire
Sep-23-19 11:30AM	Delcath Systems to Participate in Upcoming Investor Conferences GlobeNewswire

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MICHEL GERARD J	Chief Executive Officer	Apr 05	Buy	12.88	15,500	199,640	23,000	Apr 05 12:34 PM
MICHEL GERARD J	Chief Executive Officer	Dec 11	Buy	13.25	7,500	99,375	7,500	Dec 14 02:00 PM
Purpura John	Chief Operating Officer	Nov 19	Buy	12.68	1,600	20,288	14,713	Nov 20 04:05 PM
SALAMON STEVEN A J	Director	Nov 17	Buy	12.11	2,500	30,280	189,500	Nov 17 12:37 PM
Rosalind Advisors, Inc.	Director	Nov 17	Buy	12.11	2,500	30,280	191,500	Nov 19 02:27 PM
Aharon Gil	Director	Nov 16	Buy	12.00	2,000	24,000	187,000	Nov 16 01:20 PM
Rosalind Advisors, Inc.	Director	Nov 13	Buy	11.75	4,000	47,000	189,000	Nov 16 01:21 PM
SALAMON STEVEN A J	Director	Nov 13	Buy	11.51	2,000	23,020	187,000	Nov 13 01:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience